Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML
Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase I study is to investigate the combination of hypomethylating agents
with experimental peptide vaccination against four selected tumor antigens, known to be
upregulated in response to hypomethylating agents, in patients with high risk myelodysplastic
syndrome and acute myeloid leukemia.